Description du projet
L’exercice physique comme moyen de prévention contre la récidive tumorale métastatique chez les patients atteints d’un cancer colorectal
Le cancer colorectal (CCR) est le deuxième cancer le plus fréquent en Europe, provoquant chaque année le décès de près de 230 000 Européens. Environ 30 % des patients atteints de CCR développent des métastases hépatiques, qui constituent la principale cause de décès dans cette population de patients. Il a été prouvé que l’exercice physique présentait des effets antitumoraux et inhibait la croissance des tumeurs dans des modèles animaux, ce qui invite à penser que l’activité physique pourrait constituer un excellent traitement complémentaire aux traitements pharmacologiques anticancéreux. Le projet POET-mCRC, financé par l’UE, a pour objectif de déterminer si la pratique à long terme d’activités physiques peut prévenir ou retarder la récurrence des métastases chez les patients atteints de CCR. Il a également pour objectif d’identifier la dose optimale d’exercice requise pour obtenir ces effets bénéfiques.
Objectif
Every year nearly 228,000 individuals die from colorectal cancer (CRC) in Europe, the second most common cancer in Europe. Around 30% of the CRC patients develop liver metastases and these are the main cause of death. Removal of liver metastatic tumors is the primary treatment method for CRC, however, 50-75% of the patients experience a relapse of the metastases within two years, rendering adjunct treatment strategies necessary for these patients.
Preclinical work has demonstrated that exercise exerts anti-tumor effects as it is indeed able to inhibit tumor growth. Thus, exercise constitutes an excellent candidate as a complementary to the pharmacological treatment approach for CRC metastatic patients (mCRC).
My primary aim is to investigate the effects of chronic exercise on tumor recurrence after liver metastasis removal. Secondary aims are to identify the “optimal dose” of exercise to obtain the largest beneficial effect and explore the changes on circulating tumor DNA (ctDNA) as a marker of disease progression. I hypothesize that exercise training will delay or ameliorate disease recurrence in mCRC patients.
Patients will be randomized to 3 groups: control, group 1(300 min/week), group 2 (150 min/week) of combined aerobic and strength exercise training for 6 months. Study endpoints will be tumor recurrence, inflammation and immune markers, physiological adaptations and ctDNA changes.
The outcomes will provide essential knowledge about how to optimize the guidelines for exercise prescription as part of the treatment plan for mCRC patients.
The fellowship will be vital for my reintegration into academia and for me to evolve as a lead researcher. It also constitutes an ideal means of knowledge transfer between myself and the host organization as I will gain knowledge in the oncology area and advance my skills in molecular biology techniques while I convey my experience in dose-response methodology and the conduct of large-scale human exercise trials.
Champ scientifique
Programme(s)
Régime de financement
MSCA-IF-EF-CAR - CAR – Career Restart panelCoordinateur
3400 Hillerod
Danemark